PMID: 11328767May 1, 2001Paper

In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis

The Journal of Antimicrobial Chemotherapy
C LindeMats Andersson

Abstract

We have investigated the in vitro activity of antimicrobial peptides against Mycobacterium tuberculosis using a radiometric method and cfu determinations. PR-39, a proline-arginine-rich antibacterial peptide from porcine leucocytes, was found to be active against drug-susceptible as well as multi-drug-resistant (MDR) clinical isolates of M. tuberculosis. The activity of PR-39 was concentration dependent, with 80% growth inhibition of M. tuberculosis H37Rv at 50 mg/L. The MDR M. tuberculosis strains E1380/94 and P34/95 were less susceptible to PR-39, with 39 and 49% growth inhibition at 50 mg/L peptide, respectively, suggesting a lower susceptibility than strain H37Rv and drug-susceptible clinical isolates. Reduction of counts of M. tuberculosis H37Rv and the MDR M. tuberculosis strain E1380/94 by PR-39 indicated that the growth inhibition seen in the radiometric assay is due to a mycobactericidal effect of the peptide. These observations suggest that antimicrobial peptides may play an important role in host defence against MDR M. tuberculosis.

References

Sep 1, 1990·The Journal of Infectious Diseases·G S JonesB R Andersen
Apr 1, 1990·Journal of Protein Chemistry·M Ycas
Dec 1, 1987·The Journal of Infectious Diseases·A E BrownB R Andersen
Dec 1, 1986·Antimicrobial Agents and Chemotherapy·L B HeifetsP J Lindholm-Levy
Jan 1, 1995·Annual Review of Immunology·H G Boman
Sep 15, 1994·European Journal of Biochemistry·V CabiauxJ M Ruysschaert
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·R L GalloM Bernfield
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·J ShiF Blecha
Mar 1, 1996·Infection·H M HasselhornF W Tiller
Jan 1, 1997·The Journal of Peptide Research : Official Journal of the American Peptide Society·S VunnamR B Merrifield
May 1, 1997·Journal of Leukocyte Biology·H J HuangF Blecha
Feb 14, 1998·The Journal of Antimicrobial Chemotherapy·S E HoffnerB Olsson-Liljequist
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·W M ShaferR I Lehrer
Oct 24, 1998·The Journal of Biological Chemistry·Y R Chan, R L Gallo
May 20, 1999·Biopolymers·D Andreu, L Rivas
Jul 3, 1999·American Journal of Respiratory and Critical Care Medicine·B AgerberthG H Gudmundsson
Feb 24, 2001·Cellular and Molecular Life Sciences : CMLS·V BonettoH Jornvall

❮ Previous
Next ❯

Citations

Feb 8, 2003·Trends in Biotechnology·Antonella LupettiErnest K J Pauwels
Nov 7, 2003·International Journal of Antimicrobial Agents·Kim A BrogdenBrian F Tack
Nov 18, 2009·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mario Alberto Flores-Valdez, Sidharth Chopra
Dec 26, 2001·Current Opinion in Hematology·Robert I Lehrer, Tomas Ganz
Jun 3, 2009·Transboundary and Emerging Diseases·L Guenin-MacéC Demangel
Mar 13, 2013·Antimicrobial Agents and Chemotherapy·Santiago Ramón-GarcíaCharles J Thompson
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Ingeborg GrgurinaJon Y Takemoto
Sep 24, 2005·Infection and Immunity·Charlotte M A LindeMats Andersson
Apr 24, 2014·PloS One·Edwin J A VeldhuizenHenk P Haagsman
May 20, 2011·Cellular and Molecular Life Sciences : CMLS·Marco ScocchiRenato Gennaro
Feb 7, 2016·Biochimica Et Biophysica Acta·Thomas Gutsmann
Oct 12, 2010·Veterinary Immunology and Immunopathology·Sarah ScapinelloJeff L Caswell
Jun 27, 2008·Developmental and Comparative Immunology·Yongming Sang, Frank Blecha
Feb 15, 2015·The Journal of Antimicrobial Chemotherapy·Maria AbedinzadehSoroush Sardari
Oct 21, 2016·Biochimica Et Biophysica Acta·Gustavo Silveira BreguezMilton Hércules Guerra de Andrade
Apr 25, 2018·Database : the Journal of Biological Databases and Curation·Salman Sadullah UsmaniGajendra P S Raghava
Feb 24, 2016·Antimicrobial Agents and Chemotherapy·C Seth PearsonGeorges Belfort
Sep 14, 2019·Journal of Peptide Science : an Official Publication of the European Peptide Society·Sutharsana YathursanVijayalekshmi Sarojini
Dec 6, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Saad AlghamdiSabi Ur Rehman
May 1, 2021·Pharmaceuticals·Gabriel S OliveiraCátia Teixeira
Nov 21, 2016·Comparative Immunology, Microbiology and Infectious Diseases·Ravi HolaniEduardo R Cobo
May 26, 2021·Peptides·C E Valdez-MiramontesB Rivas-Santiago
Jun 1, 2021·Frontiers in Veterinary Science·Shuaibing ShiChengshui Liao
Aug 31, 2021·Frontiers in Cell and Developmental Biology·Eduardo J PatriarcaGabriella Minchiotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.